About Dynein axonemal heavy chain 11
Dynein axonemal heavy chain 11 (DNAH11) is a protein
from Homo sapiens identified by UniProt accession
Q96DT5, 4516 residues long.
MolForge cross-references it against 0 known binders and
224 disease associations.
Target properties
| Protein name | Dynein axonemal heavy chain 11 |
|---|
| UniProt accession | Q96DT5 |
|---|
| Gene | DNAH11 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 4516 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (224)
Diseases linked to this target (Open Targets).
- primary ciliary dyskinesia · score 0.77
- low density lipoprotein cholesterol measurement · score 0.52
- total cholesterol measurement · score 0.50
- vitamin D measurement · score 0.45
- apolipoprotein B measurement · score 0.43
- alcohol drinking · score 0.40
- alcohol consumption measurement · score 0.40
- bilirubin measurement · score 0.40
- HMG CoA reductase inhibitor use measurement · score 0.40
- insomnia measurement · score 0.40
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Amino-acid sequence (4516 residues)
MAAQVAAREA RDFREAPTLR LTSGAGLEAV GAVELEEEEE NEEEAAARRA RSFAQDARVR FLGGRLAMML GFTEEKWSQY LESEDNRQVL GEFLESTSPA CLVFSFAASG RLAASQEIPR DANHKLVFIS KKITESIGVN DFSQVVLFGE LPALSLGHVS AFLDEILVPV LSNKNNHKSW SCFTSQDMEY HIEVMKKKMY IFRGKMSRRT LLPIPTVAGK MDLDQNCSEN KPPSNERIIL HAIESVVIEW SHQIQEIIER DSVQRLLNGL HLSPQAELDF WMMRRENLSC IYDQLQAPVV LKMVKILTTK QSSYFPTLKD IFLAVENALL EAQDVELYLR PLRRHIQCLQ ETEFPQTRIL IAPLFHTICL IWSHSKFYNT PARVIVLLQE FCNLFINQAT AYLSPEDLLR GEIEESLEKV QVAVNILKTF KNSFFNYRKK LASYFMGRKL RPWDFQSHLV FCRFDKFLDR LIKIEDIFAT TLEFEKLERL EFGGTKGAIL NGQVHEMSEE LMELCKLFKQ STYDPSDCTN MEFESDYVAF KSKTLEFDRR LGTIICEAFF NCNGLEAAFK LLTIFGNFLE KPVVMEIFSL HYSTLVHMFN TELDVCKQLY NEHMKQIECG HVVLNKNMPF TSGNMKWAQQ VLQRLQMFWS NFASLRYLFL GNPDHALVYQ KYVEMTTLLD QFESRIYNEW KSNVDEICEF NLNQPLVKFS AINGLLCVNF DPKLVAVLRE VKYLLMLKKQ DIPDSALAIF KKRNTILKYI GNLDLLVQGY NKLKQTLLEV EYPLIEDELR AIDEQLTAAT TWLTWQDDCW GYIERVRAAT SELEHRVERT QKNVKVIQQT MRGWARCVLP PRREHRREAA FTLEDKGDLF TKKYKLIQGD GCKIHNLVEE NRKLFKANPS LDTWKIYVEF IDDIVVEGFF QAIMHDLDFF LKNTEKQLKP APFFQAQMIL LPPEIVFKPS LDREAGDGFY DLVEEMLCNS FRMSAQMNRI ATHLEIKNYQ NDMDNMLGLA EVRQEIMNRV VNVINKVLDF RNTLETHTYL WVDDRAEFMK HFLLYGHAVS SDEMDAHANE EIPEQPPTLE QFKEQIDIYE ALYVQMSKFE DFRVFDSWFK VDMKPFKVSL LTIIKKWSWM FQEHLLRFVI DSLNELQEFI KETDSGLQRE LNEGDHDGLV DIMVHLLAVR SRQRATDELF EPLKETITLL ESYGQKMPEQ VYIQLEELPE RWETTKKIAA TVRHEVSPLH NAEVTLIRKK CILFDAKQAE FRERFRHYAP LGFNAENPYT ALDKANEELE ALEEEMLQMQ ESTRLFEVAL PEYKQMKQCR KEIKLLKGLW DVIIYVRRSI DNWTKTQWRQ IHVEQMDVEL RRFAKEIWSL NKEVRVWDAY TGLEGTVKDM TASLRAITEL QSPALRDRHW HQLMKAIGVK FLINEATTLA DLLALRLHRV EDDVRRIVDK AVKELGTEKV ITEISQTWAT MKFSYEVHYR TGIPLLKSDE QLFETLEHNQ VQLQTLLQSK YVEYFIEQVL SWQNKLNIAD LVIFTWMEVQ RTWSHLESIF VCSEDIRIQL VKDARRFDGV DAEFKELMFK TAKVENVLEA TCRPNLYEKL KDLQSRLSLC EKALAEYLET KRIAFPRFYF VSSADLLDIL SKGAQPKQVT CHLAKLFDSI ADLQFEDNQD VSAHRAVGMY SKEKEYVPFQ AECECVGHVE TWLLQLEQTM QETVRHSITE AIVAYEEKPR ELWIFDFPAQ VALTSSQIWW TTDVGIAFSR LEEGYETALK DFHKKQISQL NTLITLLLGE LPPGDRQKIM TICTIDVHAR DVVAKLISQK VVSPQAFTWL SQLRHRWEDT QKHCFVNICD AQFQYFYEYL GNSPRLVITP LTDRCYITLT QSLHLTMSGA PAGPAGTGKT ETTKDLGRAL GMMVYVFNCS EQMDYKSIGN IYKGLVQTGA WGCFDEFNRI SVEVLSVVAV QVKMIHDAIR NRKKRFVFLG EAITLKPSVG IFITMNPGYA GRTELPENLK ALFRPCAMVA PDIELICEIL LVAEGFVDAR ALARKFITLY TLCKELLSKQ DHYDWGLRAI KSVLVVAGSL KRGDKNRPED QVLMRALRDF NMPKIVTDDI PVFLGLVGDL FPALDVPRRR KLHFEQMVRQ STLELRLQPE ESFILKVVQL EELLAVRHSV FVVGNAGTGK SKILRTLNRT YVNMKQKPVW NDLNPKAVTT DELFGFIHHA TREWKDGKIV YSYFIGLFSS ILREQANLKH DGPKWIVLDG DIDPMWIESL NTVMDDNKVL TLASNERIAL TPFMRLLFEI HHLRSATPAT VSRAGILYVN PQDLGWNPYV ASWIDRRRHQ SEKANLTILF DKYVPACLDK LRTSFKTITS IPESSLVQTL CVLLECLLTP ENVPSDSPKE VYEVYFVFAC IWAFGGTLLQ DQISDYQADF SRWWQKEMKA VKFPSQGTIF DYYVDHKTKK LLPWADKIAQ FTMDPDVPLQ TVLVHTTETA RLRYFMELLL EKGKPLMLVG NAGVGKTVFV GDTLASLSED YIVSRVPFNY YTTSTALQKI LEKPLEKKAG HNYGPGGNKK LIYFIDDMNM PEVDLYGTVQ PHTLIRQHID YGHWYDRQKV MLKEIHNCQY VACMNPMVGS FTINPRLQRH FTVFAFNFPS LDALNTIYGQ IFSFHFQQQA FAPSILRSGP TLIQATIAFH QTMMCNFLPT AIKFHYIFNL RDLSNVFQGI LFASPECLKG PLDLIHLWLH ESARVYGDKL IDKKDCDLFQ RRMLETAYKY FEGIDSHMLL QQPLIYCHFA DRGKDPHYMP VKDWEVLKTI LTETLDNYNE LNAAMHLVLF EDAMQHVCRI SRILRTPQGC ALLVGVGGSG KQSLSRLAAY LRGLEVFQIT LTEGYGIQEL RVDLANLYIR TGAKNMPTVF LLTDAQVLDE SFLVLINDLL ASGEIPDLFS DEDVDKIISG IHNEVHALGM VDSRENCWKF FMARVRLQLK IILCFSPVGR TLRVRARKFP AIVNCTAIDW FHAWPQEALV SVSRRFIEET KGIEPVHKDS ISLFMAHVHT TVNEMSTRYY QNERRHNYTT PKSFLEQISL FKNLLKKKQN EVSEKKERLV NGIQKLKTTA SQVGDLKARL ASQEAELQLR NHDAEALITK IGLQTEKVSR EKTIADAEER KVTAIQTEVF QKQRECEADL LKAEPALVAA TAALNTLNRV NLSELKAFPN PPIAVTNVTA AVMVLLAPRG RVPKDRSWKA AKVFMGKVDD FLQALINYDK EHIPENCLKV VNEHYLKDPE FNPNLIRTKS FAAAGLCAWV INIIKFYEVY CDVEPKRQAL AQANLELAAA TEKLEAIRKK LVDLDRNLSR LTASFEKATA EKVRCQEEVN QTNKTIKLAN RLVKELEAKK IRWGQSIKSF EAQEKTLCGD VLLTAAFVSY VGPFTRQYRQ ELVHCKWVPF LQQKVSIPLT EGLDLISMLT DDATIAAWNN EGLPSDRMST ENAAILTHCE RWPLVIDPQQ QGIKWIKNKY GMDLKVTHLG QKGFLNAIET ALAFGDVILI ENLEETIDPV LDPLLGRNTI KKGKYIRIGD KECEFNKNFR LILHTKLANP HYKPELQAQT TLLNFTVTED GLEAQLLAEV VSIERPDLEK LKLVLTKHQN DFKIELKYLE DDLLLRLSAA EGSFLDDTKL VERLEATKTT VAEIEHKVIE AKENERKINE ARECYRPVAA RASLLYFVIN DLQKINPLYQ FSLKAFNVLF HRAIEQADKV EDMQGRISIL MESITHAVFL YTSQALFEKD KLTFLSQMAF QILLRKKEID PLELDFLLRF TVEHTHLSPV DFLTSQSWSA IKAIAVMEEF RGIDRDVEGS AKQWRKWVES ECPEKEKLPQ EWKKKSLIQK LILLRAMRPD RMTYALRNFV EEKLGAKYVE RTRLDLVKAF EESSPATPIF FILSPGVDAL KDLEILGKRL GFTIDSGKFH NVSLGQGQET VAEVALEKAS KGGHWVILQN VHLVAKWLGT LEKLLERFSQ GSHRDYRVFM SAESAPTPDE HIIPQGLLEN SIKITNEPPT GMLANLHAAL YNFDQDTLEI CSKEQEFKSI LFSLCYFHAC VAGRLRFGPQ GWSRSYPFNP GDLTICASVL YNYLEANSKV PWEDLRYLFG EIMYGGHITD DWDRKLCRVY LEEFMNPSLT EDELMLAPGF AAPPYLDYAG YHQYIEEMLP PESPALYGLH PNAEIEFLTV TSNTLFRTLL EMQPRNALSG DELGQSTEEK VKNVLDDILE KLPEEFNMAE IMQKNSNRSP YVLVCFQECE RMNILIREIR ISLEQLDLSL KGELALSPAV EAQQFALSYD TVPDTWSKLA YPSTYGLAQW FNDLLLRCRE LDTWTQDLTL PAVVWLSGFF NPQSFLTAIM QTMARKNEWP LDKTRLTADV TKKTKEDYGH PPREGAYLHG LFMEGARWDT QAGTIVEARL KELACPMPVI FAKATPVDRQ ETKQTYECPV YRTKLRGPSY IWTFRLKSEE KTAKWVLAGV ALLLEA
Explore Dynein axonemal heavy chain 11 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets